Analysis: IQVIA Holdings Inc.

US:IQV

Why is IQVIA Holdings Inc. stock rising?

  • Raised full-year 2026 revenue, adjusted EBITDA, and adjusted diluted EPS guidance after stronger organic growth and updated M&A/FX assumptions.
  • Large pharma clients are asking IQVIA to prepare thousands of FTEs as AI-driven discovery expands future study portfolios.
  • Pfizer regional promotion agreement covering selected products across 23 European countries.
  • Boehringer Ingelheim selected IQVIA’s Data-as-a-Service plus platform to harmonize global commercial operations and support upcoming launches.
  • iqvia.ai agentic AI portal and marketplace launched for life sciences clients.

Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for IQVIA Holdings Inc. and 4,900+ companies.

Sign in
5-day free pass. No card required.